Publications
Detailed Information
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cortes, Javier | - |
dc.contributor.author | Rugo, Hope S. | - |
dc.contributor.author | Awada, Ahmad | - |
dc.contributor.author | Twelves, Chris | - |
dc.contributor.author | Perez, Edith A. | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Gomez-Pardo, Patricia | - |
dc.contributor.author | Schwartzberg, Lee S. | - |
dc.contributor.author | Dieras, Veronique | - |
dc.contributor.author | Yardley, Denise A. | - |
dc.contributor.author | Potter, David A. | - |
dc.contributor.author | Mailliez, Audrey | - |
dc.contributor.author | Moreno-Aspitia, Alvaro | - |
dc.contributor.author | Ahn, Jin-Seok | - |
dc.contributor.author | Zhao, Carol | - |
dc.contributor.author | Hoch, Ute | - |
dc.contributor.author | Tagliaferri, Mary | - |
dc.contributor.author | Hannah, Alison L. | - |
dc.contributor.author | O'Shaughnessy, Joyce | - |
dc.date.accessioned | 2022-03-22T09:05:12Z | - |
dc.date.available | 2022-03-22T09:05:12Z | - |
dc.date.created | 2018-09-06 | - |
dc.date.created | 2018-09-06 | - |
dc.date.created | 2018-09-06 | - |
dc.date.created | 2018-09-06 | - |
dc.date.issued | 2017-09 | - |
dc.identifier.citation | Breast Cancer Research and Treatment, Vol.165 No.2, pp.329-341 | - |
dc.identifier.issn | 0167-6806 | - |
dc.identifier.other | 51400 | - |
dc.identifier.uri | https://hdl.handle.net/10371/177128 | - |
dc.description.abstract | Purpose Conventional chemotherapy has limited activity in patients with breast cancer and brain metastases (BCBM). Etirinotecan pegol (EP), a novel long-acting topoisomerase-1 inhibitor, was designed using advanced polymer technology to preferentially accumulate in tumor tissue including brain metastases, providing sustained cytotoxic SN38 levels. Methods The phase 3 BEACON trial enrolled 852 women with heavily pretreated locally recurrent or metastatic breast cancer between 2011 and 2013. BEACON compared EP with treatment of physician's choice (TPC; eribulin, vinorelbine, gemcitabine, nab-paclitaxel, paclitaxel, ixabepilone, or docetaxel) in patients previously treated with anthracycline, taxane, and capecitabine, including those with treated, stable brain metastases. The primary endpoint, overall survival (OS), was assessed in a pre-defined subgroup of BCBM patients; an exploratory post hoc analysis adjusting for the diagnosis-specific graded prognostic assessment (GPA) index was also conducted. Results In the trial, 67 BCBM patients were randomized (EP, n = 36; TPC, n = 31). Treatment subgroups were balanced for baseline characteristics and GPA indices. EP was associated with a significant reduction in the risk of death (HR 0.51; P < 0.01) versus TPC; median OS was 10.0 and 4.8 months, respectively. Improvement in OS was observed in both poorer and better GPA prognostic groups. Survival rates at 12 months were 44.4% for EP versus 19.4% for TPC. Consistent with the overall BEACON population, fewer patients on EP experienced grade >= 3 toxicity (50 vs. 70%). Conclusions The significant improvement in survival in BCBM patients provides encouraging data for EP in this difficult-to-treat subgroup of patients. A phase three trial of EP in BCBM patients is underway | - |
dc.language | 영어 | - |
dc.publisher | Kluwer Academic Publishers | - |
dc.title | Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1007/s10549-017-4304-7 | - |
dc.citation.journaltitle | Breast Cancer Research and Treatment | - |
dc.identifier.wosid | 000407242400011 | - |
dc.identifier.scopusid | 2-s2.0-85020739938 | - |
dc.citation.endpage | 341 | - |
dc.citation.number | 2 | - |
dc.citation.startpage | 329 | - |
dc.citation.volume | 165 | - |
dc.identifier.sci | 000407242400011 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | ETIRINOTECAN PEGOL NKTR-102 | - |
dc.subject.keywordPlus | GRADED PROGNOSTIC ASSESSMENT | - |
dc.subject.keywordPlus | RECURRENT GLIOBLASTOMA | - |
dc.subject.keywordPlus | CNS METASTASES | - |
dc.subject.keywordPlus | TEMOZOLOMIDE | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | CRITERIA | - |
dc.subject.keywordPlus | SUBTYPES | - |
dc.subject.keywordAuthor | Brain metastases | - |
dc.subject.keywordAuthor | Etirinotecan pegol | - |
dc.subject.keywordAuthor | NKTR-102 | - |
dc.subject.keywordAuthor | Chemotherapy | - |
dc.subject.keywordAuthor | Metastatic breast cancer | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.